Revolutionizing Personalized Medicine: 3D Printing TechnologyEnhances Customized Drug Delivery

Granada, Spain – September 06, 2024 – The pharmaceutical industry is entering a new era with the
introduction of Gastroretentive Drug Delivery Systems (GRDDS), designed to overcome the
limitations of traditional drug delivery methods in the gastrointestinal tract. These systems, enhanced
by 3D printing technology, have shown immense potential in improving the residence time of drugs
in the stomach, while ensuring sustained drug release for optimized therapeutic outcomes.
In a groundbreaking study recently published, a team of researchers from Universidad de Sevilla,
led by Gloria Mora Castaño, Mónica Millán Jiménez, and Isidoro Caraballo, has demonstrated the
transformative power of 3D printed gastroretentive floating tablets. These innovative tablets,
developed using REGEMAT 3D’s advanced BioV1 bioprinter, represent a significant leap forward in
drug delivery technology.
The tablets, designed for controlled drug release, utilized Metformin as the model drug and
hydroxypropylmethyl cellulose as the primary carrier. Through the application of 3D printing, the
team achieved tablets with remarkable buoyancy for over 8 hours and a diffusion-controlled drug
release, highlighting the effectiveness of 3D printing in the realm of personalized medicine.
The collaboration between An Najah National University, Ghent University, and REGEMAT 3D has
opened the door for more personalized approaches to pharmaceutical treatment, offering patients
more effective therapies.
For more information about this study and other applications of 3D bioprinting, visit the Link:
https://www.mdpi.com/1999-4923/15/3/842